Ionis TTR-LRx remains on track in our studies in patients with TTR neuropathy and TTR cardiomyopathy. And APOCIII LRx also remains on track in the Phase III study in patients with FCS. We expect to begin a second Phase III study of a APOCIII LRx later this year. The second Phase III study in patients with severe hypertriglyceridemia, of over three million patients in the U.S. We also entered our late-stage pipeline with the initiation of pivotal studies for ION363 in patients with FUS-ALS. And the ION373 in patients with other disease. Because of the strong efforts of our development team, both of these medicines for rare, fatal diseases are on accelerated paths to patients. From our mid stage pipeline, just this week, positive data from the Phase II study of Ionis AGT LRx in patients with resistant hypertension were published in the Journal of American College of Cardiology.